SlideShare una empresa de Scribd logo
1 de 41
Cell line development: Reducing timelines and increasing titres by identification of host cell lines with improved characteristics 
Dr Alison Porter, FUJIFILM Diosynth Biotechnologies 
IBC Cell Line Development and Engineering, Berkeley, CA September 9, 2014 
1
FUJIFILM Diosynth Biotechnologies 
 
EU and USA operations 
 
Track record 
 
~950 staff 
 
Over 1000 cGMP batches manufactured 
 
5 Commercial Products 
 
FDA & MHRA Inspection history 
 
Extensive LSS application 
Contract Manufacturing 
& 
Process Development 
Billingham (UK) 
RTP (NC, USA)
Scope 
► 
Aims and Objectives 
► 
Host cell line development (CLD) 
• 
Directed evolution approaches 
• 
Results 
► 
CLD run-through 
• 
Experimental design 
• 
Results 
► 
Summary 
3
Aims and Objectives 
► 
To develop a mammalian expression platform which rapidly leads to efficient, robust and high quality biomanufacturing processes 
► 
New host cell line 
► 
New vector 
► 
Optimised cell line development process 
► 
Complementary medium and feed platform 
4
5 
Host cell line development
Desirable features/attributes for a host cell line 
Adapted to CD media 
Adapted to chemically defined (CD) media 
Short doubling time 
1 to 5 g/L titre for a model mAb 
Suitable product quality 
Rapid adaptation to production media 
CHO-based 
6
How do we improve host cell functional capability? 
CELL LINE ENGINEERING? 
DIRECTED EVOLUTION? 
• 
Despite decades of research and a variety of different strategies to engineer CHO cells, outcomes remained mixed 
• 
May be a need to engineer multiple targets 
• 
May require a systems-based analysis for a tailor-made response 
• 
Utilise functional heterogeneity within CHO cell populations to identify better host cell lines 
• 
We already utilise this approach 
• 
Identify high producing recombinant clones during CLD 
• 
Adaptation to serum-free chemically defined media 
• 
Potential ability to manipulate multiple phenotypic outputs 
7
Isolate a cell line with more desirable attributes from a heterogeneous cell population 
Approaches taken to obtain a host cell line with improved features/attributes 
Adaptation to chemically defined conditions 
Chemostat 
Subculture regime 
Cloning 
FACS 
Multiple rounds of sorting for cells with extended viability during batch shake flask screening 
Allows for evolution of rare mutants with desirable growth properties within a large population 
Continuous subculture (different regimes) and ability to grow in low [Gln] for lower [Amm] production 
8
Derivation of multiple DG44 variants able to grow in chemically defined (CD) culture medium 
Static culture 100% MEM-α (+10% FBS) 
Suspension 100% MEM-α (+10% FBS) 
50% CD-DG44 50% MEM-α (+10% FBS) 
75% CD-DG44 
25% MEM-α 
(+10% FBS) 
90% CD-DG44 
10% MEM-α 
(+10% FBS) 
C1 100% CD-DG44 
Suspension 75% OPTI-CHO 25% MEM-α (+10% FBS) 
80% OPTI-CHO 20% MEM-α (+10% FBS) 
90% OPTI-CHO 10% MEM-α (+10% FBS) 
C2 100% CD-DG44 
50% CD-DG44 50% OPTI-CHO 
75% CD-DG44 
25% OPTI-CHO 
C3 
100% CD-DG44 
9
0.000.250.500.751.00050100150200 Growth rate (day-1)Days in culture 
The long and winding road to CD media adaptation: The C2 story 
120 rpm 
110 rpm 
140 rpm 
Static 
100% MEMα 
+10%FBS 
75% OptiCHO 
80% OptiCHO 
85% OptiCHO 
90% OptiCHO 
100% CD DG44 
Clumping issues 
3-day sub 
3/4-day sub 
0.2 x 106 seeding 
0.3 x 106 seeding 
0.2 x 106 seeding 
1:100 anti-clump 
1:700 anti-clump 
No anti-clump 
10 
Desirable growth rate for a recombinant cell line assuming: 
• 
Seed = 0.2 x 106/mL 
• 
VCD obtained = 2.0 x 106/mL 
• 
Culture duration = 4 days 
• 
Allows a 1:10 split ratio during seed train
► 
Assess growth and metabolite profiles during an 8-day batch shake- flask screen (at which point viability < 50%) 
• 
Indication of a cell line’s potential ability to grow during extended culture 
• 
Ideally have a limited accumulation of waste metabolites (e.g. ammonium and lactate) 
Batch shake-flask screening of CD variants 
11 
051015C1C2C32B-12B-2 IVC (x 106cell∙day/mL) 0102030C1C2C32B-12B-2 Metabolite Concentration (mM) AmmLac
020406080C1C2C32B-12B-2 Transfection efficiency (%) 
► 
Assess transfectability (using GFP) and overall expression/secretion capacity (using a model mAb) 
• 
Comparison of percentage GFP positive cells 24 hours after transfection 
• 
Comparison of secreted mAb concentration 5 days post-transfection 
► 
Higher transfection efficiency and transient titre obtained with cell line C2 
C2 progressed to directed evolution stages due to superior performance during evaluation 
Higher transfection efficiency and transient titre obtained with cell line C2 
12 
01234C1C2C32B-12B-2 Transient mAb expression (mg/L) 
DG44-2B in ACF
Comparison of host cell lines obtained by directed evolution 
Adapted to CD media 
Growth rate during subculture 
IVC obtained in batch shake- flask screen 
Colony survival in semi-solid medium 
Waste metabolite (Amm and Lac) production in batch shake- flask screen 
Transient expression of mAb 1 and mAb 2 
13
051015202530 DG44-2BC2Sort-1Sort-2Sort-3Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mMDoubling time (h) 
Doubling time during subculture 
14 
► 
Improved doubling time with C2 compared to DG44-2B: ~27hrs to ~21hrs 
► 
Directed evolution approaches had little effect on doubling time
02468101214 DG44-2BC2Sort-1Sort-2Sort-3Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mMBatch shake-flask screen harvest IVC (x 106cell∙day/mL) 
IVC obtained during batch shake-flask screening 
15 
► 
Potential to increase IVC from directed evolution approaches 
► 
Higher IVC for DG44-2B may be media dependent (presence of hydrolysate)
0123 DG44-2BC2Sort-1Sort-2Sort-3Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mMmAb 2 transient expression (mg/L) 024681012 DG44-2BC2Sort-1Sort-2Sort-3Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mMmAb 1 transient expression (mg/L) 
Transient expression 
16 
► 
Improved titre obtained from C2 compared to DG44-2B 
► 
Directed evolution had variable effect: up to 3-fold increase compared to DG44-2B
020406080100120 DG44-2BC2Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mM% Colony survival in semi-solid media 
Growth in semi-solid media 
17 
► 
Improved colony survival obtained from C2 compared to DG44-2B 
► 
Directed evolution approaches have a variable effect on colony survival
024681012141618 Clone 11Sort 5Sort 41 mMClone 272 mMStat 6Clone 56Sort 66 mMClone 26Stat 2Stat 5Stat 1Clone 59DG44-2B4 mMClone 78 mMC2Stat 4Stat 3Clone 46Clone 36Average Ranking 
Average ranking used to select host cell lines to progress 
Top 5 cell lines progressed 
18
Simultaneous comparison of host cell lines: Summary 
► 
For each screen, cell lines were ranked according to their performance 
• 
The average ranking from all experiments gave an overall score for each host cell line 
► 
Top ranked host cell line isolated from cloning of parental C2 host 
• 
Clone 11 
► 
Not all cell lines identified performed better than parental C2 host 
• 
2 cell lines from the chemostat and cloning approaches ranked lower 
► 
Performance of cell lines varied between the screens: 
• 
The chemostat derived cell lines ranked towards the top when measuring growth properties in shake-flasks 
• 
In contrast, these cell lines performed poorly when assessing growth in semi-solid medium, with only low numbers of colonies being produced 
• 
Demonstrates importance of assessing multiple characteristics 
► 
Top 5 host cell lines, Clone-11, Sort-5, Sort-4, 1mM and Clone-27, were chosen to evaluate further in a ‘mini-pool’ assessment (representative of early stage stable cell line generation) 
19
Mini-pool evaluation of candidate host cell lines 
1. Transfection 
mAb 3 
mAb 1 
mAb 2 
2. Removal of HT 
3. Addition of selective pressure and plating into 96-well plates at 5000 cells/well 
4. Screening of confluent colonies by OctetTM 
5. Progression to 24- well plates 
6. Screening by OctetTM 
7. Confirmation of the top host cell line(s) for progression 
20 
Experiment biased towards mAb 1 as mAb 2 and mAb 3 have previously proven to be “difficult-to-express”
051015202530 mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3 DG44-2BClone 11Clone 27Sort 4Sort 51 mM (in1mM GLN) 1 mM (in8mM GLN) 24wp titre (mg/L) 
► 
Rank results from mini-pool evaluation combined with previous ranking results to select the top 2 host cell lines 
► 
Decision made to ensure cell lines from different directed evolution routes progressed to mitigate risk: 
• 
Sort-5 and Clone-27 
• 
DG44-2B included as a control 
24-well plate screen titre 
21
Cell Line Development Run-Through 
22
Process map of the CLD run-though 
23 
Transfection & Selection 
96-well plate screen 
Fed-batch shake-flask screen 
ClonePix™ screen 
24-well plate screen 
Batch shake-flask screen 
Stability study 
ambr15™ & Bioreactor evaluation 
Titre assessment used a generic antibody standard curve and Octet™ assay 
Titre assessment used Octet™ or ProA HPLC & a specific antibody standard curve 
• 
Clone 27 and Sort 5 assessed in CLD run-through 
• 
New FDB expression vector used with the new host cell lines 
• 
Original host/vector system included as a comparator up to the RCB stage 
• 
Original system also uses different medium/feed system 
Model mAb 1 
Host cell line 
Research cell bank
24 
CLD run-through: Transfection to recovery 
Pools from Clone-27 host 
recovery 
Pools from Sort-5 host 
Pools from DG44-2B host 
recovery 
recovery 
Transfection 
Host cell line 
2 
4 
7 
5 
3 
6 
8 
9 
12 
10 
11 
14 
13 
15 
16 
Day 0 
1 
Pools from the original host cell line (DG44-2B) had the longest recovery period 
-HT 
+ Selection reagent
CLD run-through: ClonePix™2 screening 
25 
FITC1000 Exterior Mean Intensity 
400003000020000100000 
Clone-27 
Sort-5 
DG44-2B 
Exemplar colony image 
► 
The fluorescence intensity and colony size were lower for the original host/vector system (DG44-2B)
CLD run-through: 96-well plate screen 
26 
► 
The highest titres achieved were from colonies originating from the Clone-27 host 
► 
A greater number of colonies from the original system had expression below the detection level; the max titre was considerably lower 
>150 top colonies progressed 
Clone-27 
Sort-5 
DG44-2B 
0501001502002500100200300400500600700800 Titre (mg/L) 0501001502002500100200300400500600700800 Titre (mg/L) 0501001502002500100200300400500600700800 Titre (mg/L) Colony Number
050100150200050100150200250 Titre (mg/L) 
CLD run-through: 24-well plate screen 
27 
Titre (mg/L) 
>30 top colonies progressed 
► 
The highest titres achieved were from colonies originating from the Clone-27 host 
► 
Colonies from the original host/vector system had much lower titres 
Clone-27 
Sort-5 
DG44-2B 
050100150200050100150200250 Titre (mg/L)050100150200050100150200250Colony number
28 
CLD run-through: Suspension culture 
Clone-27 
Sort-5 
DG44-2B 
43210 1009080706050 
VCD (x 106 cells/mL) 
Viability (%) 
Clone-27 
Sort-5 
DG44-2B 
Viable cell density (VCD) and viabilities achieved during a routine subculture of the top 36 producers 
Cell lines from DG44-2B host (original system): 
► 
Difficulty in adaptation to suspension 
► 
Lower VCD during routine subculture 
► 
Several top ten producers in batch screen not suitable for progression to fed-batch screen due to poor growth
29 
CLD run-through: Batch shake-flask screen 
Suspension adapted cell lines 
* 
► 
All recombinant cell lines from Clone-27 in the batch screen achieved titres above 300 mg/L 
► 
One cell line from DG44-2B produced >300 mg/L; the majority produced <100 mg/L 
Clone-27 
Sort-5 
DG44-2B 
0100200300400500600 Titre (mg/L) 0100200300400500600 Titre (mg/L) 0100200300400500600 Titre (mg/L)***** * cell growth was not acceptable for progression
CLD run-through: Growth profiles from the fed-batch shake-flask screen 
30 
► 
Non-optimised process for Clone-27 and Sort-5 
► 
A greater number of cell lines from Clone-27 host grew to >10 x 106 cells/mL; all cell lines were harvested on day 14 
► 
Only one cell line from Sort-5 host achieved high VCD; several cell lines were harvested before day 14 
► 
Cell lines from DG44-2B generally had poor growth profile and some were harvested as early as day 5 
DG44-2B 
Clone-27 
Sort-5 
Note: different medium/feed system required for DG44-2B 
051015202502468101214 VCD (x 106cells/mL) Culture time (days) 051015202502468101214Culture time (days) 051015202502468101214Culture time (days)
► 
Lactate: 
• 
Clone-27 and Sort-5 typically back-metabolise lactate 
• 
Cell lines from DG44-2B generally reached higher lactate concentrations throughout culture 
► 
Ammonium: 
• 
Harvest ammonium concentration for all cell lines from Clone-27 and Sort-5 were below 15 mM 
• 
Cell lines from DG44-2B generally had higher ammonium concentration throughout the culture and at harvest 31 
CLD run-through: Further observations from the fed-batch shake-flask screen
32 
CLD run-through: Product concentration achieved from the fed-batch shake-flask screen 
► 
A higher proportion of cell lines from Clone-27 had product titres ~2 g/L and above 
► 
Most cell lines from Sort-5 produced between 1 and 1.5 g/L 
► 
Productivity of cell lines from DG44-2B were considerably lower at <1 g/L 
Cell lines 
Clone-27 
Sort-5 
DG44-2B 
0.00.51.01.52.02.53.0 Titre (g/L) 0.00.51.01.52.02.53.0 Titre (g/L) 0.00.51.01.52.02.53.0 Titre (g/L)
33 
CLD Run-through: Specific productivity from the fed-batch shake-flask screen 
DG44-2B 
Clone-27 
Sort-5 
►Despite lower titres, cell lines from Sort-5 had higher specific productivity (QP) - due to lower growth and IVC 
►With the exception of one cell line, all cell lines from DG44-2B had QP less than 12 pg/cell·day 
01020304050 Qp (pg/cell.day) 01020304050 Qp (pg/cell.day) 01020304050 Qp (pg/cell.day)
No substantial difference in product characteristics between cell lines from different hosts 
34 
Size exclusion chromatography 
Capillary electrophoresis-SDS (reduced) 
N-linked glycans 
Cation-exchange chromatography 
Exemplar Overlay graph 
• 
The majority of the product from all recombinant cell lines in monomeric form (≥98%) 
Exemplar electropherogram 
• 
Major peaks identified as LC and HC 
• 
Very low percentage of non-glycosylated (~0.5%) and other variants. 
• 
Low percentage of acidic and basic variants 
• 
Lower percentage of main peak and additional basic peaks for DG44-2B* cell lines * Different medium/feed system 
Basic peaks overlays 
Cell lines from new hosts 
Cell lines from DG44-2B 
• 
Predominant glycan species did not change between host cell lines 
• 
Man5 varied from 2 to 15% between cell lines 
• 
Some minor differences with DG44-2B but this had different medium / feed system 
• 
Adapting all cell lines to this system removed the minor differences 
Clone-27 derived cell line 
• 
No considerable aggregation detected 
CONFIDENTIAL
35 
Comparison of top producers in the ambr15TM screen 
point size: Qp 
► 
The highest titre was achieved by a Clone-27 derived cell line 
• 
3 g/L 
► 
Cell lines from Sort-5 generally had higher Qp but lower IVC 
Sort-5 
Clone-27 0.00.51.01.52.02.53.03.50500100015002000250030003500400045005000 Harvest Titre(g/L) IVC (x 106cells.h/mL)
3.02.52.01.51.0 Product Concentration (g/L) 
36 
Decision on lead host cell line 
Box plot summary of key data for cell lines derived from Clone-27 and Sort-5 
Clone-27 
Fed-batch shake-flask 
ambr15TM 
Sort-5 
Sort-5 
200150100500 
Qp (pcd) 
4540353025201510 
► 
Clone-27 selected as lead host cell line: 
► 
Clone-27 cell lines achieved the highest titres and IVCs in both shake-flask and ambr15TM screens 
► 
Difference in QP reduced between Sort-5 and Clone-27 cell lines in ambr15TM 
Clone-27 
Fed-batch shake flask 
ambr15TM 
Fed-batch shake flask 
ambr15TM 
IVC (x 106 cells.d/mL) 
Clone-27 
Sort-5 
Sort-5 
Clone-27 
Clone-27 
Sort-5 
Sort-5 
Clone-27
37 
New hosts/vector system 
Original host/vector system 
Suitable PQ 
Better growth 
Higher Titres 
More undesirable waste metabolites 
Poor growth & productivity 
CLD run-through: Summary 
The new host/vector system performed better than the original system at every screening stage 
Vector 
Host 
+ 
Suitable PQ 
CLD run-through
► 
Four directed evolution approaches used to develop new host cell lines 
• 
FACS; cloning; chemostat; subculture regime 
► 
Multiple host cell lines with improved characteristics identified 
• 
Growth rate and expression capability 
• 
Need to look at multiple characteristics when assessing potential new host cell lines demonstrated 
► 
Top two potential host cell lines assessed in full CLD process 
• 
Performance of both superior to original system, which had been included as a comparator 
► 
A final new host cell line was selected 
• 
Product concentrations up to 3 g/L observed in ambr15™ using a non- optimised process 
• 
Improved growth characteristics 
• 
Acceptable product characteristics 
Summary 
38
Summary - continued 
► 
Aim: To develop a mammalian expression platform which rapidly leads to efficient, robust and high quality biomanufacturing processes 
► 
New host cell line 
► 
New vector 
► 
Optimised cell line development process 
► 
Complementary medium and feed platform – under development 
39 
 
 

► 
Adeline Bayard 
► 
Naz Dadehbeigi 
► 
Clare Lovelady 
► 
Leon Pybus 
► 
Fay Saunders 
► 
Alison Young 
► 
All members of the Mammalian Cell Culture R&D team – UK and USA 
► 
Analytical Development, FDB 
Acknowledgements 
40
41

Más contenido relacionado

La actualidad más candente

CHARACTERISATION OF CELLS LINES
CHARACTERISATION OF CELLS LINESCHARACTERISATION OF CELLS LINES
CHARACTERISATION OF CELLS LINESAishwaryaDande1
 
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy Development
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentWebinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy Development
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentBIS Research Inc.
 
Mammalian & Bacterial Expression
Mammalian & Bacterial ExpressionMammalian & Bacterial Expression
Mammalian & Bacterial ExpressionJesús C. Morales
 
The Awesome Science of Animal Cell Culture...
The Awesome Science of Animal Cell Culture...The Awesome Science of Animal Cell Culture...
The Awesome Science of Animal Cell Culture...Alok Bharadwaj N
 
A Systems Biology Approach to Natural Products Research
A Systems Biology Approach to Natural Products ResearchA Systems Biology Approach to Natural Products Research
A Systems Biology Approach to Natural Products ResearchHuda Nazeer
 
MONOCLONAL ANTIBODIES ( MAB )
MONOCLONAL ANTIBODIES ( MAB )MONOCLONAL ANTIBODIES ( MAB )
MONOCLONAL ANTIBODIES ( MAB )N Anusha
 
Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...
Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...
Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...Chris Willmott
 
Animal Cell Culture and its application
Animal Cell Culture and its applicationAnimal Cell Culture and its application
Animal Cell Culture and its applicationDr. SONAM PANDEY
 
Expedited Development & Review of New Drugs (LI)
Expedited Development & Review of New Drugs (LI)Expedited Development & Review of New Drugs (LI)
Expedited Development & Review of New Drugs (LI)Jason Moore, MS, MBA, RAC
 
De novo genome assembly - T.Seemann - IMB winter school 2016 - brisbane, au ...
De novo genome assembly  - T.Seemann - IMB winter school 2016 - brisbane, au ...De novo genome assembly  - T.Seemann - IMB winter school 2016 - brisbane, au ...
De novo genome assembly - T.Seemann - IMB winter school 2016 - brisbane, au ...Torsten Seemann
 
Precision Medicine: Research Presentation
Precision Medicine: Research PresentationPrecision Medicine: Research Presentation
Precision Medicine: Research PresentationShelagh McLellan
 
Biosimilars ppt presentation
Biosimilars ppt presentationBiosimilars ppt presentation
Biosimilars ppt presentationmeghanamegha23
 
Pharmacogenomics and drug development
Pharmacogenomics and drug developmentPharmacogenomics and drug development
Pharmacogenomics and drug developmentAjitKumarSingh62
 
Techniques of cell cloning by kk
Techniques of cell cloning  by kkTechniques of cell cloning  by kk
Techniques of cell cloning by kkKAUSHAL SAHU
 
RITUXIMAB PLANT DESIGN
RITUXIMAB PLANT DESIGNRITUXIMAB PLANT DESIGN
RITUXIMAB PLANT DESIGNAnil Vibhute
 
What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...Canadian Cancer Survivor Network
 

La actualidad más candente (20)

Application of cell line
Application of cell lineApplication of cell line
Application of cell line
 
CHARACTERISATION OF CELLS LINES
CHARACTERISATION OF CELLS LINESCHARACTERISATION OF CELLS LINES
CHARACTERISATION OF CELLS LINES
 
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy Development
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentWebinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy Development
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy Development
 
Mammalian & Bacterial Expression
Mammalian & Bacterial ExpressionMammalian & Bacterial Expression
Mammalian & Bacterial Expression
 
The Awesome Science of Animal Cell Culture...
The Awesome Science of Animal Cell Culture...The Awesome Science of Animal Cell Culture...
The Awesome Science of Animal Cell Culture...
 
3 d printing
3 d printing3 d printing
3 d printing
 
A Systems Biology Approach to Natural Products Research
A Systems Biology Approach to Natural Products ResearchA Systems Biology Approach to Natural Products Research
A Systems Biology Approach to Natural Products Research
 
MONOCLONAL ANTIBODIES ( MAB )
MONOCLONAL ANTIBODIES ( MAB )MONOCLONAL ANTIBODIES ( MAB )
MONOCLONAL ANTIBODIES ( MAB )
 
Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...
Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...
Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...
 
Animal tissue culture lecture 2
Animal tissue culture lecture 2Animal tissue culture lecture 2
Animal tissue culture lecture 2
 
Animal Cell Culture and its application
Animal Cell Culture and its applicationAnimal Cell Culture and its application
Animal Cell Culture and its application
 
Expedited Development & Review of New Drugs (LI)
Expedited Development & Review of New Drugs (LI)Expedited Development & Review of New Drugs (LI)
Expedited Development & Review of New Drugs (LI)
 
De novo genome assembly - T.Seemann - IMB winter school 2016 - brisbane, au ...
De novo genome assembly  - T.Seemann - IMB winter school 2016 - brisbane, au ...De novo genome assembly  - T.Seemann - IMB winter school 2016 - brisbane, au ...
De novo genome assembly - T.Seemann - IMB winter school 2016 - brisbane, au ...
 
Precision Medicine: Research Presentation
Precision Medicine: Research PresentationPrecision Medicine: Research Presentation
Precision Medicine: Research Presentation
 
Biosimilars ppt presentation
Biosimilars ppt presentationBiosimilars ppt presentation
Biosimilars ppt presentation
 
Pharmacogenomics and drug development
Pharmacogenomics and drug developmentPharmacogenomics and drug development
Pharmacogenomics and drug development
 
Techniques of cell cloning by kk
Techniques of cell cloning  by kkTechniques of cell cloning  by kk
Techniques of cell cloning by kk
 
RITUXIMAB PLANT DESIGN
RITUXIMAB PLANT DESIGNRITUXIMAB PLANT DESIGN
RITUXIMAB PLANT DESIGN
 
What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...
 
Bioequivalence studies
Bioequivalence studiesBioequivalence studies
Bioequivalence studies
 

Destacado

Cell line development ol
Cell line development olCell line development ol
Cell line development olAnkita Gurao
 
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...fujifilmdiosynth
 
Animal cell lines culturing
Animal cell lines culturingAnimal cell lines culturing
Animal cell lines culturingGirija Anakala
 
Development of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsDevelopment of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsNational Institute of Biologics
 
Principles of cell culture
Principles of cell culturePrinciples of cell culture
Principles of cell cultureMegha Bedekar
 
Animal tissue culture
Animal tissue cultureAnimal tissue culture
Animal tissue cultureVeena Shriram
 
chalo celebrate kare - CenturyPly Social media campaign
chalo celebrate kare - CenturyPly Social media campaign chalo celebrate kare - CenturyPly Social media campaign
chalo celebrate kare - CenturyPly Social media campaign Webitude
 
Appointment letter_Karan
Appointment letter_KaranAppointment letter_Karan
Appointment letter_KaranKaran Bhawsar
 
5-soft presentation
5-soft presentation5-soft presentation
5-soft presentation5-soft
 
Social media falcons
Social media falconsSocial media falcons
Social media falconsmeghna1490
 
โครงงาน
โครงงานโครงงาน
โครงงานnamnoi1
 
Apresentação unos life oficial 2.0 (portugues)
Apresentação unos life oficial 2.0 (portugues)Apresentação unos life oficial 2.0 (portugues)
Apresentação unos life oficial 2.0 (portugues)Fernando Viana
 
Poster presentation - Documented Clonality Report for Regulatory Submission
Poster presentation - Documented Clonality Report for Regulatory SubmissionPoster presentation - Documented Clonality Report for Regulatory Submission
Poster presentation - Documented Clonality Report for Regulatory SubmissionIanTaylor50
 
Presentation by Systimunne - at the Cell Line Development & Engineering Summi...
Presentation by Systimunne - at the Cell Line Development & Engineering Summi...Presentation by Systimunne - at the Cell Line Development & Engineering Summi...
Presentation by Systimunne - at the Cell Line Development & Engineering Summi...IanTaylor50
 
High-throughput Miniaturized Bioreactors for Cell Culture Process Developmen...
High-throughput Miniaturized Bioreactors for Cell Culture  Process Developmen...High-throughput Miniaturized Bioreactors for Cell Culture  Process Developmen...
High-throughput Miniaturized Bioreactors for Cell Culture Process Developmen...KBI Biopharma
 

Destacado (20)

Cell line development ol
Cell line development olCell line development ol
Cell line development ol
 
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
 
Animal cell lines culturing
Animal cell lines culturingAnimal cell lines culturing
Animal cell lines culturing
 
Development of a cutting edge CHO cell culture medium
Development of a cutting edge CHO cell culture mediumDevelopment of a cutting edge CHO cell culture medium
Development of a cutting edge CHO cell culture medium
 
Development of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsDevelopment of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applications
 
Principles of cell culture
Principles of cell culturePrinciples of cell culture
Principles of cell culture
 
Animal tissue culture
Animal tissue cultureAnimal tissue culture
Animal tissue culture
 
Valitacell Technology
Valitacell TechnologyValitacell Technology
Valitacell Technology
 
chalo celebrate kare - CenturyPly Social media campaign
chalo celebrate kare - CenturyPly Social media campaign chalo celebrate kare - CenturyPly Social media campaign
chalo celebrate kare - CenturyPly Social media campaign
 
Appointment letter_Karan
Appointment letter_KaranAppointment letter_Karan
Appointment letter_Karan
 
5-soft presentation
5-soft presentation5-soft presentation
5-soft presentation
 
Keeping Cool on a Budget
Keeping Cool on a Budget Keeping Cool on a Budget
Keeping Cool on a Budget
 
Social media falcons
Social media falconsSocial media falcons
Social media falcons
 
โครงงาน
โครงงานโครงงาน
โครงงาน
 
Apresentação unos life oficial 2.0 (portugues)
Apresentação unos life oficial 2.0 (portugues)Apresentação unos life oficial 2.0 (portugues)
Apresentação unos life oficial 2.0 (portugues)
 
Leto2014
Leto2014Leto2014
Leto2014
 
Final ptsd vs cptsd 1
Final ptsd vs cptsd 1Final ptsd vs cptsd 1
Final ptsd vs cptsd 1
 
Poster presentation - Documented Clonality Report for Regulatory Submission
Poster presentation - Documented Clonality Report for Regulatory SubmissionPoster presentation - Documented Clonality Report for Regulatory Submission
Poster presentation - Documented Clonality Report for Regulatory Submission
 
Presentation by Systimunne - at the Cell Line Development & Engineering Summi...
Presentation by Systimunne - at the Cell Line Development & Engineering Summi...Presentation by Systimunne - at the Cell Line Development & Engineering Summi...
Presentation by Systimunne - at the Cell Line Development & Engineering Summi...
 
High-throughput Miniaturized Bioreactors for Cell Culture Process Developmen...
High-throughput Miniaturized Bioreactors for Cell Culture  Process Developmen...High-throughput Miniaturized Bioreactors for Cell Culture  Process Developmen...
High-throughput Miniaturized Bioreactors for Cell Culture Process Developmen...
 

Similar a Cell Line Development: Reducing timelines and increasing titres

Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesMilliporeSigma
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesMerck Life Sciences
 
SMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.pptSMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.ppthirbogeremew2
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...MilliporeSigma
 
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...MilliporeSigma
 
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...Merck Life Sciences
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsMerck Life Sciences
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsMilliporeSigma
 
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesHIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesKBI Biopharma
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationMerck Life Sciences
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationMilliporeSigma
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...MilliporeSigma
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Merck Life Sciences
 
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...Merck Life Sciences
 
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...MilliporeSigma
 
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...KBI Biopharma
 
LakePharma’s CHO-GSN Platform for Stable Cell Line Generation
LakePharma’s CHO-GSN Platform for Stable Cell Line GenerationLakePharma’s CHO-GSN Platform for Stable Cell Line Generation
LakePharma’s CHO-GSN Platform for Stable Cell Line GenerationJin Di, Ph.D.
 
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...MilliporeSigma
 
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...KBI Biopharma
 
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Merck Life Sciences
 

Similar a Cell Line Development: Reducing timelines and increasing titres (20)

Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell Lines
 
Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell Lines
 
SMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.pptSMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.ppt
 
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
 
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
 
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
Risk Mitigation in Cell Line Development: Regulatory Considerations and Impac...
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey Platforms
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey Platforms
 
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & PossibilitiesHIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
HIV Vaccines Process Development & Manufacturing - Pitfalls & Possibilities
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...
 
Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...Investing in Process Development for Increased MSC Production in Stirred Tank...
Investing in Process Development for Increased MSC Production in Stirred Tank...
 
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
 
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
 
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
Debottlenecking Manufacturing Capacity: Initiating cell culture manufacturing...
 
LakePharma’s CHO-GSN Platform for Stable Cell Line Generation
LakePharma’s CHO-GSN Platform for Stable Cell Line GenerationLakePharma’s CHO-GSN Platform for Stable Cell Line Generation
LakePharma’s CHO-GSN Platform for Stable Cell Line Generation
 
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
 
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
 
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...
 

Último

Oxo-Acids of Halogens and their Salts.pptx
Oxo-Acids of Halogens and their Salts.pptxOxo-Acids of Halogens and their Salts.pptx
Oxo-Acids of Halogens and their Salts.pptxfarhanvvdk
 
well logging & petrophysical analysis.pptx
well logging & petrophysical analysis.pptxwell logging & petrophysical analysis.pptx
well logging & petrophysical analysis.pptxzaydmeerab121
 
GenAI talk for Young at Wageningen University & Research (WUR) March 2024
GenAI talk for Young at Wageningen University & Research (WUR) March 2024GenAI talk for Young at Wageningen University & Research (WUR) March 2024
GenAI talk for Young at Wageningen University & Research (WUR) March 2024Jene van der Heide
 
Charateristics of the Angara-A5 spacecraft launched from the Vostochny Cosmod...
Charateristics of the Angara-A5 spacecraft launched from the Vostochny Cosmod...Charateristics of the Angara-A5 spacecraft launched from the Vostochny Cosmod...
Charateristics of the Angara-A5 spacecraft launched from the Vostochny Cosmod...Christina Parmionova
 
DNA isolation molecular biology practical.pptx
DNA isolation molecular biology practical.pptxDNA isolation molecular biology practical.pptx
DNA isolation molecular biology practical.pptxGiDMOh
 
Science (Communication) and Wikipedia - Potentials and Pitfalls
Science (Communication) and Wikipedia - Potentials and PitfallsScience (Communication) and Wikipedia - Potentials and Pitfalls
Science (Communication) and Wikipedia - Potentials and PitfallsDobusch Leonhard
 
Q4-Mod-1c-Quiz-Projectile-333344444.pptx
Q4-Mod-1c-Quiz-Projectile-333344444.pptxQ4-Mod-1c-Quiz-Projectile-333344444.pptx
Q4-Mod-1c-Quiz-Projectile-333344444.pptxtuking87
 
Quarter 4_Grade 8_Digestive System Structure and Functions
Quarter 4_Grade 8_Digestive System Structure and FunctionsQuarter 4_Grade 8_Digestive System Structure and Functions
Quarter 4_Grade 8_Digestive System Structure and FunctionsCharlene Llagas
 
Observational constraints on mergers creating magnetism in massive stars
Observational constraints on mergers creating magnetism in massive starsObservational constraints on mergers creating magnetism in massive stars
Observational constraints on mergers creating magnetism in massive starsSérgio Sacani
 
Explainable AI for distinguishing future climate change scenarios
Explainable AI for distinguishing future climate change scenariosExplainable AI for distinguishing future climate change scenarios
Explainable AI for distinguishing future climate change scenariosZachary Labe
 
Forensic limnology of diatoms by Sanjai.pptx
Forensic limnology of diatoms by Sanjai.pptxForensic limnology of diatoms by Sanjai.pptx
Forensic limnology of diatoms by Sanjai.pptxkumarsanjai28051
 
Combining Asynchronous Task Parallelism and Intel SGX for Secure Deep Learning
Combining Asynchronous Task Parallelism and Intel SGX for Secure Deep LearningCombining Asynchronous Task Parallelism and Intel SGX for Secure Deep Learning
Combining Asynchronous Task Parallelism and Intel SGX for Secure Deep Learningvschiavoni
 
WEEK 4 PHYSICAL SCIENCE QUARTER 3 FOR G11
WEEK 4 PHYSICAL SCIENCE QUARTER 3 FOR G11WEEK 4 PHYSICAL SCIENCE QUARTER 3 FOR G11
WEEK 4 PHYSICAL SCIENCE QUARTER 3 FOR G11GelineAvendao
 
whole genome sequencing new and its types including shortgun and clone by clone
whole genome sequencing new  and its types including shortgun and clone by clonewhole genome sequencing new  and its types including shortgun and clone by clone
whole genome sequencing new and its types including shortgun and clone by clonechaudhary charan shingh university
 
final waves properties grade 7 - third quarter
final waves properties grade 7 - third quarterfinal waves properties grade 7 - third quarter
final waves properties grade 7 - third quarterHanHyoKim
 
The Sensory Organs, Anatomy and Function
The Sensory Organs, Anatomy and FunctionThe Sensory Organs, Anatomy and Function
The Sensory Organs, Anatomy and FunctionJadeNovelo1
 
GLYCOSIDES Classification Of GLYCOSIDES Chemical Tests Glycosides
GLYCOSIDES Classification Of GLYCOSIDES  Chemical Tests GlycosidesGLYCOSIDES Classification Of GLYCOSIDES  Chemical Tests Glycosides
GLYCOSIDES Classification Of GLYCOSIDES Chemical Tests GlycosidesNandakishor Bhaurao Deshmukh
 
Loudspeaker- direct radiating type and horn type.pptx
Loudspeaker- direct radiating type and horn type.pptxLoudspeaker- direct radiating type and horn type.pptx
Loudspeaker- direct radiating type and horn type.pptxpriyankatabhane
 
DECOMPOSITION PATHWAYS of TM-alkyl complexes.pdf
DECOMPOSITION PATHWAYS of TM-alkyl complexes.pdfDECOMPOSITION PATHWAYS of TM-alkyl complexes.pdf
DECOMPOSITION PATHWAYS of TM-alkyl complexes.pdfDivyaK787011
 

Último (20)

Oxo-Acids of Halogens and their Salts.pptx
Oxo-Acids of Halogens and their Salts.pptxOxo-Acids of Halogens and their Salts.pptx
Oxo-Acids of Halogens and their Salts.pptx
 
well logging & petrophysical analysis.pptx
well logging & petrophysical analysis.pptxwell logging & petrophysical analysis.pptx
well logging & petrophysical analysis.pptx
 
GenAI talk for Young at Wageningen University & Research (WUR) March 2024
GenAI talk for Young at Wageningen University & Research (WUR) March 2024GenAI talk for Young at Wageningen University & Research (WUR) March 2024
GenAI talk for Young at Wageningen University & Research (WUR) March 2024
 
Let’s Say Someone Did Drop the Bomb. Then What?
Let’s Say Someone Did Drop the Bomb. Then What?Let’s Say Someone Did Drop the Bomb. Then What?
Let’s Say Someone Did Drop the Bomb. Then What?
 
Charateristics of the Angara-A5 spacecraft launched from the Vostochny Cosmod...
Charateristics of the Angara-A5 spacecraft launched from the Vostochny Cosmod...Charateristics of the Angara-A5 spacecraft launched from the Vostochny Cosmod...
Charateristics of the Angara-A5 spacecraft launched from the Vostochny Cosmod...
 
DNA isolation molecular biology practical.pptx
DNA isolation molecular biology practical.pptxDNA isolation molecular biology practical.pptx
DNA isolation molecular biology practical.pptx
 
Science (Communication) and Wikipedia - Potentials and Pitfalls
Science (Communication) and Wikipedia - Potentials and PitfallsScience (Communication) and Wikipedia - Potentials and Pitfalls
Science (Communication) and Wikipedia - Potentials and Pitfalls
 
Q4-Mod-1c-Quiz-Projectile-333344444.pptx
Q4-Mod-1c-Quiz-Projectile-333344444.pptxQ4-Mod-1c-Quiz-Projectile-333344444.pptx
Q4-Mod-1c-Quiz-Projectile-333344444.pptx
 
Quarter 4_Grade 8_Digestive System Structure and Functions
Quarter 4_Grade 8_Digestive System Structure and FunctionsQuarter 4_Grade 8_Digestive System Structure and Functions
Quarter 4_Grade 8_Digestive System Structure and Functions
 
Observational constraints on mergers creating magnetism in massive stars
Observational constraints on mergers creating magnetism in massive starsObservational constraints on mergers creating magnetism in massive stars
Observational constraints on mergers creating magnetism in massive stars
 
Explainable AI for distinguishing future climate change scenarios
Explainable AI for distinguishing future climate change scenariosExplainable AI for distinguishing future climate change scenarios
Explainable AI for distinguishing future climate change scenarios
 
Forensic limnology of diatoms by Sanjai.pptx
Forensic limnology of diatoms by Sanjai.pptxForensic limnology of diatoms by Sanjai.pptx
Forensic limnology of diatoms by Sanjai.pptx
 
Combining Asynchronous Task Parallelism and Intel SGX for Secure Deep Learning
Combining Asynchronous Task Parallelism and Intel SGX for Secure Deep LearningCombining Asynchronous Task Parallelism and Intel SGX for Secure Deep Learning
Combining Asynchronous Task Parallelism and Intel SGX for Secure Deep Learning
 
WEEK 4 PHYSICAL SCIENCE QUARTER 3 FOR G11
WEEK 4 PHYSICAL SCIENCE QUARTER 3 FOR G11WEEK 4 PHYSICAL SCIENCE QUARTER 3 FOR G11
WEEK 4 PHYSICAL SCIENCE QUARTER 3 FOR G11
 
whole genome sequencing new and its types including shortgun and clone by clone
whole genome sequencing new  and its types including shortgun and clone by clonewhole genome sequencing new  and its types including shortgun and clone by clone
whole genome sequencing new and its types including shortgun and clone by clone
 
final waves properties grade 7 - third quarter
final waves properties grade 7 - third quarterfinal waves properties grade 7 - third quarter
final waves properties grade 7 - third quarter
 
The Sensory Organs, Anatomy and Function
The Sensory Organs, Anatomy and FunctionThe Sensory Organs, Anatomy and Function
The Sensory Organs, Anatomy and Function
 
GLYCOSIDES Classification Of GLYCOSIDES Chemical Tests Glycosides
GLYCOSIDES Classification Of GLYCOSIDES  Chemical Tests GlycosidesGLYCOSIDES Classification Of GLYCOSIDES  Chemical Tests Glycosides
GLYCOSIDES Classification Of GLYCOSIDES Chemical Tests Glycosides
 
Loudspeaker- direct radiating type and horn type.pptx
Loudspeaker- direct radiating type and horn type.pptxLoudspeaker- direct radiating type and horn type.pptx
Loudspeaker- direct radiating type and horn type.pptx
 
DECOMPOSITION PATHWAYS of TM-alkyl complexes.pdf
DECOMPOSITION PATHWAYS of TM-alkyl complexes.pdfDECOMPOSITION PATHWAYS of TM-alkyl complexes.pdf
DECOMPOSITION PATHWAYS of TM-alkyl complexes.pdf
 

Cell Line Development: Reducing timelines and increasing titres

  • 1. Cell line development: Reducing timelines and increasing titres by identification of host cell lines with improved characteristics Dr Alison Porter, FUJIFILM Diosynth Biotechnologies IBC Cell Line Development and Engineering, Berkeley, CA September 9, 2014 1
  • 2. FUJIFILM Diosynth Biotechnologies  EU and USA operations  Track record  ~950 staff  Over 1000 cGMP batches manufactured  5 Commercial Products  FDA & MHRA Inspection history  Extensive LSS application Contract Manufacturing & Process Development Billingham (UK) RTP (NC, USA)
  • 3. Scope ► Aims and Objectives ► Host cell line development (CLD) • Directed evolution approaches • Results ► CLD run-through • Experimental design • Results ► Summary 3
  • 4. Aims and Objectives ► To develop a mammalian expression platform which rapidly leads to efficient, robust and high quality biomanufacturing processes ► New host cell line ► New vector ► Optimised cell line development process ► Complementary medium and feed platform 4
  • 5. 5 Host cell line development
  • 6. Desirable features/attributes for a host cell line Adapted to CD media Adapted to chemically defined (CD) media Short doubling time 1 to 5 g/L titre for a model mAb Suitable product quality Rapid adaptation to production media CHO-based 6
  • 7. How do we improve host cell functional capability? CELL LINE ENGINEERING? DIRECTED EVOLUTION? • Despite decades of research and a variety of different strategies to engineer CHO cells, outcomes remained mixed • May be a need to engineer multiple targets • May require a systems-based analysis for a tailor-made response • Utilise functional heterogeneity within CHO cell populations to identify better host cell lines • We already utilise this approach • Identify high producing recombinant clones during CLD • Adaptation to serum-free chemically defined media • Potential ability to manipulate multiple phenotypic outputs 7
  • 8. Isolate a cell line with more desirable attributes from a heterogeneous cell population Approaches taken to obtain a host cell line with improved features/attributes Adaptation to chemically defined conditions Chemostat Subculture regime Cloning FACS Multiple rounds of sorting for cells with extended viability during batch shake flask screening Allows for evolution of rare mutants with desirable growth properties within a large population Continuous subculture (different regimes) and ability to grow in low [Gln] for lower [Amm] production 8
  • 9. Derivation of multiple DG44 variants able to grow in chemically defined (CD) culture medium Static culture 100% MEM-α (+10% FBS) Suspension 100% MEM-α (+10% FBS) 50% CD-DG44 50% MEM-α (+10% FBS) 75% CD-DG44 25% MEM-α (+10% FBS) 90% CD-DG44 10% MEM-α (+10% FBS) C1 100% CD-DG44 Suspension 75% OPTI-CHO 25% MEM-α (+10% FBS) 80% OPTI-CHO 20% MEM-α (+10% FBS) 90% OPTI-CHO 10% MEM-α (+10% FBS) C2 100% CD-DG44 50% CD-DG44 50% OPTI-CHO 75% CD-DG44 25% OPTI-CHO C3 100% CD-DG44 9
  • 10. 0.000.250.500.751.00050100150200 Growth rate (day-1)Days in culture The long and winding road to CD media adaptation: The C2 story 120 rpm 110 rpm 140 rpm Static 100% MEMα +10%FBS 75% OptiCHO 80% OptiCHO 85% OptiCHO 90% OptiCHO 100% CD DG44 Clumping issues 3-day sub 3/4-day sub 0.2 x 106 seeding 0.3 x 106 seeding 0.2 x 106 seeding 1:100 anti-clump 1:700 anti-clump No anti-clump 10 Desirable growth rate for a recombinant cell line assuming: • Seed = 0.2 x 106/mL • VCD obtained = 2.0 x 106/mL • Culture duration = 4 days • Allows a 1:10 split ratio during seed train
  • 11. ► Assess growth and metabolite profiles during an 8-day batch shake- flask screen (at which point viability < 50%) • Indication of a cell line’s potential ability to grow during extended culture • Ideally have a limited accumulation of waste metabolites (e.g. ammonium and lactate) Batch shake-flask screening of CD variants 11 051015C1C2C32B-12B-2 IVC (x 106cell∙day/mL) 0102030C1C2C32B-12B-2 Metabolite Concentration (mM) AmmLac
  • 12. 020406080C1C2C32B-12B-2 Transfection efficiency (%) ► Assess transfectability (using GFP) and overall expression/secretion capacity (using a model mAb) • Comparison of percentage GFP positive cells 24 hours after transfection • Comparison of secreted mAb concentration 5 days post-transfection ► Higher transfection efficiency and transient titre obtained with cell line C2 C2 progressed to directed evolution stages due to superior performance during evaluation Higher transfection efficiency and transient titre obtained with cell line C2 12 01234C1C2C32B-12B-2 Transient mAb expression (mg/L) DG44-2B in ACF
  • 13. Comparison of host cell lines obtained by directed evolution Adapted to CD media Growth rate during subculture IVC obtained in batch shake- flask screen Colony survival in semi-solid medium Waste metabolite (Amm and Lac) production in batch shake- flask screen Transient expression of mAb 1 and mAb 2 13
  • 14. 051015202530 DG44-2BC2Sort-1Sort-2Sort-3Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mMDoubling time (h) Doubling time during subculture 14 ► Improved doubling time with C2 compared to DG44-2B: ~27hrs to ~21hrs ► Directed evolution approaches had little effect on doubling time
  • 15. 02468101214 DG44-2BC2Sort-1Sort-2Sort-3Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mMBatch shake-flask screen harvest IVC (x 106cell∙day/mL) IVC obtained during batch shake-flask screening 15 ► Potential to increase IVC from directed evolution approaches ► Higher IVC for DG44-2B may be media dependent (presence of hydrolysate)
  • 16. 0123 DG44-2BC2Sort-1Sort-2Sort-3Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mMmAb 2 transient expression (mg/L) 024681012 DG44-2BC2Sort-1Sort-2Sort-3Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mMmAb 1 transient expression (mg/L) Transient expression 16 ► Improved titre obtained from C2 compared to DG44-2B ► Directed evolution had variable effect: up to 3-fold increase compared to DG44-2B
  • 17. 020406080100120 DG44-2BC2Sort-4Sort-5Sort-6Clone-7Clone-11Clone-26Clone-27Clone-36Clone-46Clone-56Clone-59Stat-1Stat-2Stat-3Stat-4Stat-5Stat-68 mM6 mM4 mM2 mM1 mM% Colony survival in semi-solid media Growth in semi-solid media 17 ► Improved colony survival obtained from C2 compared to DG44-2B ► Directed evolution approaches have a variable effect on colony survival
  • 18. 024681012141618 Clone 11Sort 5Sort 41 mMClone 272 mMStat 6Clone 56Sort 66 mMClone 26Stat 2Stat 5Stat 1Clone 59DG44-2B4 mMClone 78 mMC2Stat 4Stat 3Clone 46Clone 36Average Ranking Average ranking used to select host cell lines to progress Top 5 cell lines progressed 18
  • 19. Simultaneous comparison of host cell lines: Summary ► For each screen, cell lines were ranked according to their performance • The average ranking from all experiments gave an overall score for each host cell line ► Top ranked host cell line isolated from cloning of parental C2 host • Clone 11 ► Not all cell lines identified performed better than parental C2 host • 2 cell lines from the chemostat and cloning approaches ranked lower ► Performance of cell lines varied between the screens: • The chemostat derived cell lines ranked towards the top when measuring growth properties in shake-flasks • In contrast, these cell lines performed poorly when assessing growth in semi-solid medium, with only low numbers of colonies being produced • Demonstrates importance of assessing multiple characteristics ► Top 5 host cell lines, Clone-11, Sort-5, Sort-4, 1mM and Clone-27, were chosen to evaluate further in a ‘mini-pool’ assessment (representative of early stage stable cell line generation) 19
  • 20. Mini-pool evaluation of candidate host cell lines 1. Transfection mAb 3 mAb 1 mAb 2 2. Removal of HT 3. Addition of selective pressure and plating into 96-well plates at 5000 cells/well 4. Screening of confluent colonies by OctetTM 5. Progression to 24- well plates 6. Screening by OctetTM 7. Confirmation of the top host cell line(s) for progression 20 Experiment biased towards mAb 1 as mAb 2 and mAb 3 have previously proven to be “difficult-to-express”
  • 21. 051015202530 mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3mAb 1mAb 2mAb 3 DG44-2BClone 11Clone 27Sort 4Sort 51 mM (in1mM GLN) 1 mM (in8mM GLN) 24wp titre (mg/L) ► Rank results from mini-pool evaluation combined with previous ranking results to select the top 2 host cell lines ► Decision made to ensure cell lines from different directed evolution routes progressed to mitigate risk: • Sort-5 and Clone-27 • DG44-2B included as a control 24-well plate screen titre 21
  • 22. Cell Line Development Run-Through 22
  • 23. Process map of the CLD run-though 23 Transfection & Selection 96-well plate screen Fed-batch shake-flask screen ClonePix™ screen 24-well plate screen Batch shake-flask screen Stability study ambr15™ & Bioreactor evaluation Titre assessment used a generic antibody standard curve and Octet™ assay Titre assessment used Octet™ or ProA HPLC & a specific antibody standard curve • Clone 27 and Sort 5 assessed in CLD run-through • New FDB expression vector used with the new host cell lines • Original host/vector system included as a comparator up to the RCB stage • Original system also uses different medium/feed system Model mAb 1 Host cell line Research cell bank
  • 24. 24 CLD run-through: Transfection to recovery Pools from Clone-27 host recovery Pools from Sort-5 host Pools from DG44-2B host recovery recovery Transfection Host cell line 2 4 7 5 3 6 8 9 12 10 11 14 13 15 16 Day 0 1 Pools from the original host cell line (DG44-2B) had the longest recovery period -HT + Selection reagent
  • 25. CLD run-through: ClonePix™2 screening 25 FITC1000 Exterior Mean Intensity 400003000020000100000 Clone-27 Sort-5 DG44-2B Exemplar colony image ► The fluorescence intensity and colony size were lower for the original host/vector system (DG44-2B)
  • 26. CLD run-through: 96-well plate screen 26 ► The highest titres achieved were from colonies originating from the Clone-27 host ► A greater number of colonies from the original system had expression below the detection level; the max titre was considerably lower >150 top colonies progressed Clone-27 Sort-5 DG44-2B 0501001502002500100200300400500600700800 Titre (mg/L) 0501001502002500100200300400500600700800 Titre (mg/L) 0501001502002500100200300400500600700800 Titre (mg/L) Colony Number
  • 27. 050100150200050100150200250 Titre (mg/L) CLD run-through: 24-well plate screen 27 Titre (mg/L) >30 top colonies progressed ► The highest titres achieved were from colonies originating from the Clone-27 host ► Colonies from the original host/vector system had much lower titres Clone-27 Sort-5 DG44-2B 050100150200050100150200250 Titre (mg/L)050100150200050100150200250Colony number
  • 28. 28 CLD run-through: Suspension culture Clone-27 Sort-5 DG44-2B 43210 1009080706050 VCD (x 106 cells/mL) Viability (%) Clone-27 Sort-5 DG44-2B Viable cell density (VCD) and viabilities achieved during a routine subculture of the top 36 producers Cell lines from DG44-2B host (original system): ► Difficulty in adaptation to suspension ► Lower VCD during routine subculture ► Several top ten producers in batch screen not suitable for progression to fed-batch screen due to poor growth
  • 29. 29 CLD run-through: Batch shake-flask screen Suspension adapted cell lines * ► All recombinant cell lines from Clone-27 in the batch screen achieved titres above 300 mg/L ► One cell line from DG44-2B produced >300 mg/L; the majority produced <100 mg/L Clone-27 Sort-5 DG44-2B 0100200300400500600 Titre (mg/L) 0100200300400500600 Titre (mg/L) 0100200300400500600 Titre (mg/L)***** * cell growth was not acceptable for progression
  • 30. CLD run-through: Growth profiles from the fed-batch shake-flask screen 30 ► Non-optimised process for Clone-27 and Sort-5 ► A greater number of cell lines from Clone-27 host grew to >10 x 106 cells/mL; all cell lines were harvested on day 14 ► Only one cell line from Sort-5 host achieved high VCD; several cell lines were harvested before day 14 ► Cell lines from DG44-2B generally had poor growth profile and some were harvested as early as day 5 DG44-2B Clone-27 Sort-5 Note: different medium/feed system required for DG44-2B 051015202502468101214 VCD (x 106cells/mL) Culture time (days) 051015202502468101214Culture time (days) 051015202502468101214Culture time (days)
  • 31. ► Lactate: • Clone-27 and Sort-5 typically back-metabolise lactate • Cell lines from DG44-2B generally reached higher lactate concentrations throughout culture ► Ammonium: • Harvest ammonium concentration for all cell lines from Clone-27 and Sort-5 were below 15 mM • Cell lines from DG44-2B generally had higher ammonium concentration throughout the culture and at harvest 31 CLD run-through: Further observations from the fed-batch shake-flask screen
  • 32. 32 CLD run-through: Product concentration achieved from the fed-batch shake-flask screen ► A higher proportion of cell lines from Clone-27 had product titres ~2 g/L and above ► Most cell lines from Sort-5 produced between 1 and 1.5 g/L ► Productivity of cell lines from DG44-2B were considerably lower at <1 g/L Cell lines Clone-27 Sort-5 DG44-2B 0.00.51.01.52.02.53.0 Titre (g/L) 0.00.51.01.52.02.53.0 Titre (g/L) 0.00.51.01.52.02.53.0 Titre (g/L)
  • 33. 33 CLD Run-through: Specific productivity from the fed-batch shake-flask screen DG44-2B Clone-27 Sort-5 ►Despite lower titres, cell lines from Sort-5 had higher specific productivity (QP) - due to lower growth and IVC ►With the exception of one cell line, all cell lines from DG44-2B had QP less than 12 pg/cell·day 01020304050 Qp (pg/cell.day) 01020304050 Qp (pg/cell.day) 01020304050 Qp (pg/cell.day)
  • 34. No substantial difference in product characteristics between cell lines from different hosts 34 Size exclusion chromatography Capillary electrophoresis-SDS (reduced) N-linked glycans Cation-exchange chromatography Exemplar Overlay graph • The majority of the product from all recombinant cell lines in monomeric form (≥98%) Exemplar electropherogram • Major peaks identified as LC and HC • Very low percentage of non-glycosylated (~0.5%) and other variants. • Low percentage of acidic and basic variants • Lower percentage of main peak and additional basic peaks for DG44-2B* cell lines * Different medium/feed system Basic peaks overlays Cell lines from new hosts Cell lines from DG44-2B • Predominant glycan species did not change between host cell lines • Man5 varied from 2 to 15% between cell lines • Some minor differences with DG44-2B but this had different medium / feed system • Adapting all cell lines to this system removed the minor differences Clone-27 derived cell line • No considerable aggregation detected CONFIDENTIAL
  • 35. 35 Comparison of top producers in the ambr15TM screen point size: Qp ► The highest titre was achieved by a Clone-27 derived cell line • 3 g/L ► Cell lines from Sort-5 generally had higher Qp but lower IVC Sort-5 Clone-27 0.00.51.01.52.02.53.03.50500100015002000250030003500400045005000 Harvest Titre(g/L) IVC (x 106cells.h/mL)
  • 36. 3.02.52.01.51.0 Product Concentration (g/L) 36 Decision on lead host cell line Box plot summary of key data for cell lines derived from Clone-27 and Sort-5 Clone-27 Fed-batch shake-flask ambr15TM Sort-5 Sort-5 200150100500 Qp (pcd) 4540353025201510 ► Clone-27 selected as lead host cell line: ► Clone-27 cell lines achieved the highest titres and IVCs in both shake-flask and ambr15TM screens ► Difference in QP reduced between Sort-5 and Clone-27 cell lines in ambr15TM Clone-27 Fed-batch shake flask ambr15TM Fed-batch shake flask ambr15TM IVC (x 106 cells.d/mL) Clone-27 Sort-5 Sort-5 Clone-27 Clone-27 Sort-5 Sort-5 Clone-27
  • 37. 37 New hosts/vector system Original host/vector system Suitable PQ Better growth Higher Titres More undesirable waste metabolites Poor growth & productivity CLD run-through: Summary The new host/vector system performed better than the original system at every screening stage Vector Host + Suitable PQ CLD run-through
  • 38. ► Four directed evolution approaches used to develop new host cell lines • FACS; cloning; chemostat; subculture regime ► Multiple host cell lines with improved characteristics identified • Growth rate and expression capability • Need to look at multiple characteristics when assessing potential new host cell lines demonstrated ► Top two potential host cell lines assessed in full CLD process • Performance of both superior to original system, which had been included as a comparator ► A final new host cell line was selected • Product concentrations up to 3 g/L observed in ambr15™ using a non- optimised process • Improved growth characteristics • Acceptable product characteristics Summary 38
  • 39. Summary - continued ► Aim: To develop a mammalian expression platform which rapidly leads to efficient, robust and high quality biomanufacturing processes ► New host cell line ► New vector ► Optimised cell line development process ► Complementary medium and feed platform – under development 39   
  • 40. ► Adeline Bayard ► Naz Dadehbeigi ► Clare Lovelady ► Leon Pybus ► Fay Saunders ► Alison Young ► All members of the Mammalian Cell Culture R&D team – UK and USA ► Analytical Development, FDB Acknowledgements 40
  • 41. 41